Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Bristol Meyrs Squibb pays $800 million for ADC from SystImmune
by Laura Howes
December 16, 2023
| A version of this story appeared in
Volume 101, Issue 41
Bristol Myers Squibb will pay $800 million for an antibody drug conjugate (ADC) from SystImmune, a clinical-stage biopharmaceutical company. BL-B01D1 is a bispecific ADC that targets EGFR and HER3 proteins to treat lung and breast cancer. The two companies will codevelop and commercialize the drug in the US. SystImmune retains exclusive rights in China, while BMS’s license gives it exclusivity in the rest of the world.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter